Serina Therapeutics (SER) CSO exercises options and sells 4,100 shares

Rhea-AI Filing Summary

Serina Therapeutics reported an insider equity transaction by its Chief Scientific Officer, Randall Moreadith. On 12/23/2025, he exercised a stock option to buy 4,100 shares of common stock at an exercise price of $0.06 per share, then sold 4,100 shares of common stock at a sale price of $2.6 per share on the same date.

After this transaction, he continued to hold 352,186 stock options directly, each with an exercise price of $0.06 and an expiration date of 05/06/2031. The filing notes that these stock options are fully vested, meaning they are already earned and exercisable under the plan terms.

Insider Trade Summary

Net Seller: 4,100 shares ($10,660)

Net Sell 3 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 4,100 shs ($11K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	4,100	$0.00	--
Exercise	Common Stock	4,100	$0.06	$246.00
Sale	Common Stock	4,100	$2.60	$11K

Holdings After Transaction: Stock Option (right to buy) — 352,186 shares (Direct); Common Stock — 4,100 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/23/2025		M		4,100	A	$0.06	4,100	D
Common Stock	12/23/2025		S		4,100	D	$2.6	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	12/23/2025		M			4,100	(1)	05/06/2031	Common Stock	4,100	$0	352,186	D

Explanation of Responses:

1. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	12/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Serina Therapeutics (SER) disclose?

Serina Therapeutics disclosed that its Chief Scientific Officer, Randall Moreadith, exercised 4,100 stock options and sold 4,100 shares of common stock on 12/23/2025.

Who is the reporting person in this Serina Therapeutics Form 4 filing?

The reporting person is Randall Moreadith, who serves as the Chief Scientific Officer of Serina Therapeutics, Inc.

How many Serina Therapeutics shares were bought and sold in this transaction?

Randall Moreadith exercised options to acquire 4,100 shares of common stock and then sold 4,100 shares of common stock on the same date.

At what prices were the Serina Therapeutics options exercised and shares sold?

The stock options were exercised at an exercise price of $0.06 per share, and the common stock was sold at a price of $2.6 per share.

How many Serina Therapeutics stock options does the insider hold after the transaction?

Following the reported transaction, Randall Moreadith beneficially owned 352,186 stock options directly, each with an exercise price of $0.06 and an expiration date of 05/06/2031.

Are the remaining Serina Therapeutics stock options held by the insider vested?

Yes. The filing states that the stock options are fully vested, meaning they are currently exercisable under the applicable equity plan.